128 related articles for article (PubMed ID: 12031937)
1. Comment on thalidomide usage in myeloma.
Myers B
Haematologica; 2002 Jun; 87(6):ELT29. PubMed ID: 12031937
[No Abstract] [Full Text] [Related]
2. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
3. Ultra low dose thalidomide in elderly patients with myeloma.
Bowcock SJ; Minchom A; Yates LR; Ryali MM
Br J Haematol; 2008 Apr; 141(1):120-2. PubMed ID: 18279458
[No Abstract] [Full Text] [Related]
4. Ultra low dose thalidomide in myeloma revisited.
Patrick HE; Bowcock SJ
Br J Haematol; 2010 Jul; 150(2):232-4. PubMed ID: 20346009
[No Abstract] [Full Text] [Related]
5. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
7. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
Dimopoulos MA; Anagnostopoulos A; Terpos E; Repoussis P; Zomas A; Katodritou E; Kyrtsonis MC; Delibasi S; Vassou A; Pouli A; Zervas K; Anagnostopoulos N; Maniatis A;
Haematologica; 2006 Feb; 91(2):252-4. PubMed ID: 16461313
[TBL] [Abstract][Full Text] [Related]
8. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
Ural AU; Avcu F
Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715
[No Abstract] [Full Text] [Related]
10. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Huston A; Brown J; Roodman GD
Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
[No Abstract] [Full Text] [Related]
11. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
[No Abstract] [Full Text] [Related]
14. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
[TBL] [Abstract][Full Text] [Related]
15. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
[No Abstract] [Full Text] [Related]
17. Eastern Cooperative Oncology Group E1A00: phase III randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma.
Greipp PR
Clin Adv Hematol Oncol; 2003 Mar; 1(3):188-9. PubMed ID: 16224404
[No Abstract] [Full Text] [Related]
18. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide and dexamethasone: therapy for multiple myeloma.
Kumar S; Rajkumar SV
Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
